Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols
- PMID: 25484902
- PMCID: PMC4251645
- DOI: 10.1155/2014/697675
Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols
Abstract
Objective. Several studies showed better outcome in adolescents and young adults with acute lymphoblastic leukemia (ALL) treated with pediatrics protocols than similarly aged patients treated with adults protocols, while other studies showed similar outcome of both protocols. We conducted this study to compare the outcome of our pediatrics and adults therapeutic protocols in treatment of adolescents ALL. Patients and Methods. We retrospectively reviewed files of 86 consecutive adolescent ALL patients aged 15-18 years who attended to outpatients clinic from January 2003 to January 2010. 32 out of 86 were treated with pediatrics adopted BFM 90 high risk protocol while 54 were treated with adults adopted BFM protocol. We analyzed the effect of different treatment protocols on achieving complete remission (CR), disease-free survival (DFS), and overall survival (OS). Results. The 2 patients groups have almost similar characteristics. The CR was significantly higher in pediatrics protocol 96% versus 89% (P = 0.001). Despite the fact that the toxicity profiles were higher in pediatrics protocol, they were tolerable. Moreover, the pediatrics protocol resulted in superior outcome in EFS 67% versus 39% (P = 0.001), DFS 65% versus 41% (P = 0.000), and OS 67% versus 45% (P = 0.000). Conclusion. Our study's findings recommend using intensified pediatrics inspired protocol to treat adolescents with acute lymphoblastic leukemia.
Figures
Similar articles
-
Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.Blood Adv. 2021 Mar 9;5(5):1178-1193. doi: 10.1182/bloodadvances.2020003526. Blood Adv. 2021. PMID: 33635331 Free PMC article.
-
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.J Clin Oncol. 2008 Apr 10;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265. J Clin Oncol. 2008. PMID: 18398150 Clinical Trial.
-
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.J Clin Oncol. 2003 Mar 1;21(5):774-80. doi: 10.1200/JCO.2003.02.053. Epub 2003 Mar 1. J Clin Oncol. 2003. PMID: 12610173 Clinical Trial.
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
-
Pediatrics.Buffalo Med J. 1903 Sep;43(2):111-113. Buffalo Med J. 1903. PMID: 36888334 Free PMC article. Review. No abstract available.
Cited by
-
Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).J Cancer Res Clin Oncol. 2023 Apr;149(4):1473-1483. doi: 10.1007/s00432-022-04021-1. Epub 2022 May 4. J Cancer Res Clin Oncol. 2023. PMID: 35507103 Free PMC article.
-
The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia.Iran J Cancer Prev. 2016 Aug 10;9(4):e5045. doi: 10.17795/ijcp-5045. eCollection 2016 Aug. Iran J Cancer Prev. 2016. PMID: 27761210 Free PMC article.
-
Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.Leuk Lymphoma. 2020 Feb;61(2):420-428. doi: 10.1080/10428194.2019.1666379. Epub 2019 Sep 16. Leuk Lymphoma. 2020. PMID: 31526067 Free PMC article.
-
Acute Lymphoblastic Leukemia in a Young Adult Presenting as Hepatitis and Acute Kidney Injury.J Investig Med High Impact Case Rep. 2016 Sep 22;4(3):2324709616665866. doi: 10.1177/2324709616665866. eCollection 2016 Jul-Sep. J Investig Med High Impact Case Rep. 2016. PMID: 27722178 Free PMC article.
-
Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.J Adolesc Young Adult Oncol. 2017 Mar;6(1):53-61. doi: 10.1089/jayao.2016.0049. Epub 2016 Oct 25. J Adolesc Young Adult Oncol. 2017. PMID: 27779442 Free PMC article.
References
-
- Pui C.-H., Campana D., Pei D., Bowman W. P., Sandlund J. T., Kaste S. C., Ribeiro R. C., Rubnitz J. E., Raimondi S. C., Onciu M., Coustan-Smith E., Kun L. E., Jeha S., Cheng C., Howard S. C., Simmons V., Bayles A., Metzger M. L., Boyett J. M., Leung W., Handgretinger R., Downing J. R., Evans W. E., Relling M. V. Treating childhood acute lymphoblastic leukemia without cranial irradiation. The New England Journal of Medicine. 2009;360(26):2730–2741. doi: 10.1056/NEJMoa0900386. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources